DATE: Thursday, September 10, 2015
TIME: 1 pm ET
LINK: http://tinyurl.com/sep10pre
This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the association’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
Selected Recent Company Highlights
Enrollment began and first patient has been treated in ADRESU Japanese urinary incontinence approval trial
Cytori began enrollment and first patient has been treated in US Phase III/pivotal scleroderma STAR trial
Cytori announced Japanese approval trial for Stress Urinary Incontinence using Cytori Cell Therapy
Cytori reported its Licensee, Kerastem Technologies, received conditional approval from FDA for a Phase II Alopecia Trial
Cytori completed enrollment of US Phase IIb Osteoarthritis Trial, ACT-OA trial, 6-month data expected in Q1 2016
Celution processed adipose derived cell therapy was granted orphan drug status for treatment of scleroderma in European Union
Cytori reported positive topline 12-month follow-up data on SCLERADEC-I Trial
Cytori and Lorem Vascular were granted regulatory clearance for Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China , and initial purchase order placed by Lorem Vascular
CYTX
http://www.wallstreetpoint.com/three-biotech-stocks-are-tumbling-cytori-therapeutics-inc-nasdaqcytx-spectrum-pharmaceuticals-inc-nasdaqsppipdl-biopharma-inc-nasdaqpdli/727696/
http://www.4-traders.com/CYTORI-THERAPEUTICS-INC-8997/consensus/
Bastante movimiento últimamente en la empresa, tiene un precio objetivo medio de 4 $ pero me conformo con que alcance los 1$ . Saludos